Stockscreener 앱 받기
2.09
17.91%
-0.45
Immunitybio Inc 주식(IBRX)의 최신 뉴스
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
ImmunityBio stock sinks after FDA issues RTF letter - Investing.com Australia
ImmunityBio stock sinks after FDA issues RTF letter By Investing.com - Investing.com UK
ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency'S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May - marketscreener.com
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 20 - Business Wire
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting - The Globe and Mail
Wainwright maintains $8 target on ImmunityBio shares post-AUA By Investing.com - Investing.com India
Wainwright maintains $8 target on ImmunityBio shares post-AUA - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
IBRX LAWSUIT ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio's Bladder Cancer Treatment Shows High Cystectomy Avoidance, Long-Term Response - marketscreener.com
IBRX Study Reveals Promising Results for Non-Muscle Invasive Bla - GuruFocus
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up - marketscreener.com
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best i - StreetInsider
SHAREHOLDER ALERT: Potential Recovery for ImmunityBio, Inc. (IBRX) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting - BioSpace
Why ImmunityBio, Inc. (IBRX) Declined on Wednesday - Insider Monkey
Economic Uncertainties Batter Trading in These 10 Firms - Insider Monkey
ImmunityBio sees Q1 sales surge, submits FDA applications By Investing.com - Investing.com South Africa
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia - BioSpace
ImmunityBio Completes FDA License Application Submissions - marketscreener.com
Immunitybio Announces FDA Submissions Of Supplemental BLA For Nmibc Papillary Disease And For Expanded Access Of Anktiva®To Treat Lymphopenia - marketscreener.com
ImmunityBio sees Q1 sales surge, submits FDA applications - Investing.com
Why ImmunityBio Inc. (IBRX) Skyrocketed On Monday? - MSN
Is ImmunityBio Stock Heading Upwards? - timothysykes.com
ImmunityBio (IBRX) Secures $75 Million Financing for Growth - GuruFocus
ImmunityBio raises $75 million in direct offering - The Pharma Letter
ImmunityBio settles securities class action lawsuit for $10.5 million - Claim Depot
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple - Insider Monkey
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
ImmunityBio secures $75 million in direct offering - Investing.com Australia
ImmunityBio secures $75 million in direct offering By Investing.com - Investing.com South Africa
SEC Form 424B5 filed by ImmunityBio Inc. - Quantisnow
ImmunityBio Stock: What’s Driving the Market? - timothysykes.com
Rallybio ends development in rare disorder; ImmunityBio raises $75M - Endpoints News
ImmunityBio Launches $75 Million Registered Direct Offering - MarketScreener
ImmunityBio (IBRX) Secures $75 Million in Direct Offering - GuruFocus
ImmunityBio raises $75 million in equity financing - MSN
ImmunityBio Secures $75 Million in Direct Offering - TipRanks
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor - Business Wire
IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) - ACCESS Newswire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - BioSpace
0.35%
0.36%
자본화:
|
볼륨(24시간):